Document is current
Any future updates will be listed below
-
Authors
Zhang, Minghe
Yan, Xinchun
Shi, Minghui
Li, Ruihang
Pi, Ziwei
Ren, Xiangying
Wang, Yongbo
Yan, Siyu
Wang, Yunyun
Jin, Yinghui
Wang, Xinghuan http://orcid.org/0000-0002-2877-4345
-
Funding
Funding for this research was provided by:
Department of Science and Technology, Hubei Provincial People's Government (2020FCA048)
- License Information
-
More Information
Article History
Received: 6 April 2022
Accepted: 31 May 2022
First Online: 23 June 2022
Declarations
:
: Not applicable.
: Not applicable.
: XingHuan Wang led the favipiravir randomized controlled trial and it was supported by the National Key Research and Development Program of China (2020YFC0844400); XingHuan Wang, and YingHui Jin reported research projects involving infection of healthcare workers during this epidemic, which was supported by Special Project for Emergency of Hubei Province (2020FCA008). XingHuan Wang and YingHui Jin developed two COVID-19 guidelines (A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) and Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version)). All other authors declare no competing interests.
